Page last updated: 2024-11-06

2,3,3',4,4'-pentachlorobiphenyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2,3,3',4,4'-pentachlorobiphenyl is a highly chlorinated polychlorinated biphenyl (PCB) congener. It is a persistent organic pollutant (POP) that has been widely used in industrial applications, such as electrical insulation, hydraulic fluids, and plasticizers. Due to its persistence and bioaccumulation, it has been found to contaminate the environment, including soil, water, and wildlife. 2,3,3',4,4'-pentachlorobiphenyl is known to be toxic to various organisms, including humans, and is associated with a range of adverse health effects, such as liver damage, immune suppression, and endocrine disruption. Its widespread contamination and potential health risks have made it a subject of intensive research and environmental regulation. The compound is synthesized through various industrial processes involving the chlorination of biphenyl. Due to its high persistence and bioaccumulation, it is studied to understand its environmental fate and transport, as well as its potential effects on human health and ecosystems. Research on 2,3,3',4,4'-pentachlorobiphenyl aims to develop strategies for its remediation and prevention of further contamination.'

Cross-References

ID SourceID
PubMed CID36188
CHEMBL ID341816
CHEBI ID81518
SCHEMBL ID2282125
MeSH IDM0186065

Synonyms (34)

Synonym
1,1'-biphenyl, 2,3,3',4,4'-pentachloro-
biphenyl, 2,3,3',4,4'-pentachloro-
2,3,3'4,4'-pentachloro-1,1'-biphenyl
brn 2283442
pcb 105
3,4,2',3',4'-pentachlorobiphenyl
2,3,3',4,4'-pentachlorobiphenyl
1,1'-biphenyl, 2,3,3'4,4'-pentachloro-
2,3,4,3',4'-pentachlorobiphenyl
pencb
2,3,3',4,4'-pcb
pcb-105
CHEMBL341816 ,
2,3,4,3',4'-pentachloro-biphenyl
chebi:81518 ,
1,2,3-trichloro-4-(3,4-dichlorophenyl)benzene
32598-14-4
C18116
0s596v3mlh ,
unii-0s596v3mlh
bdbm50408330
pcb no 105
AKOS015903433
1,1'-biphenyl,2,3,3',4,4'-pentachloro-
SCHEMBL2282125
WIDHRBRBACOVOY-UHFFFAOYSA-N
2,3,3',4,4'-pentachloro-1,1'-biphenyl
DTXSID8038306 ,
pcb no 105, analytical standard
pcb no. 105 10 microg/ml in isooctane
pcb no. 105
Q27155438
pcb no. 105 100 microg/ml in isooctane
dtxcid6018306

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Based on our previous work, this congener is relatively less toxic than PCB 126, 118, and 153 and is similar in toxicity to 156."( Toxicity of PCB 105 in the rat liver: an ultrastructural and biochemical study.
Chu, I; Gilroy, C; Singh, A; Villeneuve, DC,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" A prior study developed a cross-species quantitative adverse outcome pathway (qAOP) which can predict full dose-response curves of early life stage mortality for any species of bird or fish exposed to DLCs using the species- and chemical-specific 50% effect concentration (EC50) from an in vitro AhR transactivation assay with COS-7 cells."( Predicting Early Life Stage Mortality in Birds and Fishes from Exposure to Low-Potency Agonists of the Aryl Hydrocarbon Receptor: A Cross-Species Quantitative Adverse Outcome Pathway Approach.
Doering, JA; Dubiel, J; Wiseman, S, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
trichlorobenzeneAny member of the class of chlorobenzenes carrying three chloro substituents at unspecified positions.
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
pentachlorobiphenylAny polychlorobiphenyl with molecular formula C12H5Cl5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A1Rattus norvegicus (Norway rat)EC50 (µMol)4.26580.00152.205710.0000AID39064
Aryl hydrocarbon receptorHomo sapiens (human)EC50 (µMol)4.26580.00151.976910.0000AID39064
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
blood vessel developmentAryl hydrocarbon receptorHomo sapiens (human)
regulation of adaptive immune responseAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of T cell mediated immune response to tumor cellAryl hydrocarbon receptorHomo sapiens (human)
regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
xenobiotic metabolic processAryl hydrocarbon receptorHomo sapiens (human)
apoptotic processAryl hydrocarbon receptorHomo sapiens (human)
response to xenobiotic stimulusAryl hydrocarbon receptorHomo sapiens (human)
response to toxic substanceAryl hydrocarbon receptorHomo sapiens (human)
regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
cAMP-mediated signalingAryl hydrocarbon receptorHomo sapiens (human)
intracellular receptor signaling pathwayAryl hydrocarbon receptorHomo sapiens (human)
regulation of B cell proliferationAryl hydrocarbon receptorHomo sapiens (human)
circadian regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of inflammatory responseAryl hydrocarbon receptorHomo sapiens (human)
cellular response to molecule of bacterial originAryl hydrocarbon receptorHomo sapiens (human)
cellular response to cAMPAryl hydrocarbon receptorHomo sapiens (human)
cellular response to forskolinAryl hydrocarbon receptorHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxineAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
transcription cis-regulatory region bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAryl hydrocarbon receptorHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
TFIID-class transcription factor complex bindingAryl hydrocarbon receptorHomo sapiens (human)
transcription coactivator bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activityAryl hydrocarbon receptorHomo sapiens (human)
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
protein bindingAryl hydrocarbon receptorHomo sapiens (human)
TBP-class protein bindingAryl hydrocarbon receptorHomo sapiens (human)
protein homodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
protein heterodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
Hsp90 protein bindingAryl hydrocarbon receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAryl hydrocarbon receptorHomo sapiens (human)
E-box bindingAryl hydrocarbon receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nuclear aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nucleoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytosolAryl hydrocarbon receptorHomo sapiens (human)
chromatinAryl hydrocarbon receptorHomo sapiens (human)
transcription regulator complexAryl hydrocarbon receptorHomo sapiens (human)
protein-containing complexAryl hydrocarbon receptorHomo sapiens (human)
cytosolic aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID39064Affinity on cytosolic Aromatic hydrocarbon receptor (Ah)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (21.05)18.2507
2000's4 (21.05)29.6817
2010's7 (36.84)24.3611
2020's4 (21.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.08 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (9.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (90.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]